US2016184256A1PendingUtilityA1

Method of treating disorders of the cardiovascular system and a pharmaceutical agent

Assignee: EPSHTEIN OLEG ILIICHPriority: Jun 20, 2000Filed: Mar 2, 2016Published: Jun 30, 2016
Est. expiryJun 20, 2020(expired)· nominal 20-yr term from priority
A61P 37/00A61P 9/10A61P 9/00A61P 43/00A61P 3/04C07K 16/241A61P 25/28A61K 41/0004A61P 29/00A61P 25/16A61P 25/30C07K 16/26C07K 16/249C07K 2317/77A61K 2039/505C07K 2317/73C07K 16/246A61K 2039/545C07K 16/245C07K 16/243C07K 16/00A61K 39/39583A61P 25/34C07K 2317/75C07K 16/2806A61P 3/10A61P 25/36C07K 16/44A61P 31/12C07K 16/40A61P 25/24A61K 31/277A61P 25/32A61P 31/00C07K 16/24C07K 16/28C07K 16/248A61P 25/18C07K 16/22
65
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method of treating a pathological syndrome includes administration of an activated form of ultra-low doses of antibodies to an antigen, wherein said activated form is obtained by repeated consecutive dilution combined with external impact, and the antigen is a substance or a pharmaceutical agent exerting influence upon the mechanisms of formation of this particular pathological syndrome. Pharmaceutical agent for treating a pathological syndrome contains activated form of ultra-low doses of monoclonal, polyclonal or natural antibodies to an antigen, wherein said activated form is prepared by means of repeated consecutive dilution and external treatment, predominantly based on homeopathic technology, and said antigen is a substance or a drug acting as a direct cause of the pathological syndrome or involved in regulation of mechanisms of its formation. At that, activated forms of ultra-low doses of antibodies are raised against antigens of exogenous or endogenous origin, against autologous antigens, fetal antigens; anti-idiotypic antibodies are used too.

Claims

exact text as granted — not AI-modified
1 - 16 . (canceled) 
     
     
         17 . A method of treating disorders of the cardiovascular system in a patient, said method comprising administering to said patient a homeopathically potentized form of at least one antibody to an antigen, which antigen is a molecule capable of regulating cardiovascular disorders. 
     
     
         18 . (canceled) 
     
     
         19 . The method of  claim 17 , wherein the antigen is an exogenous molecule. 
     
     
         20 . The method of  claim 17 , wherein the antigen is a hapten. 
     
     
         21 .- 31 . (canceled) 
     
     
         32 . The method of  claim 17 , wherein the antigen is verapamil. 
     
     
         33 .- 36 . (canceled) 
     
     
         37 . The method of  claim 17 , wherein the disorder of the cardiovascular system is ischemic heart disease. 
     
     
         38 . The method of  claim 17 , wherein the disorder of the cardiovascular system is angina. 
     
     
         39 . The method of  claim 17 , wherein the disorder of the cardiovascular system is tachycardia. 
     
     
         40 . The method of  claim 17 , wherein the disorder of the cardiovascular system is bradyarrhythmia. 
     
     
         41 . The method of  claim 17 , wherein the disorder of the cardiovascular system is cardiac failure. 
     
     
         42 . The method of  claim 17 , wherein the disorder of the cardiovascular system is rheumatic heart disease. 
     
     
         43 . The method of  claim 17 , wherein the disorder of the cardiovascular system is cardiac arrhythmia. 
     
     
         44 . The method of  claim 17 , wherein the disorder of the cardiovascular system is ventricular extrasystoles. 
     
     
         45 . The method of  claim 17 , wherein the disorder of the cardiovascular system is atrial extrasystoles. 
     
     
         46 . The method of  claim 17 , wherein the disorder of the cardiovascular system is myocardiopathy.

Join the waitlist — get patent alerts

Track US2016184256A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.